Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs PF 6747775 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 10 Oct 2017 Planned End Date changed from 1 Feb 2020 to 1 Mar 2020.
- 12 Sep 2017 Results (n=44, data cut off: 3 Feb 2017) presented at the 42nd European Society for Medical Oncology Congress
- 25 Oct 2016 Planned number of patients changed from 200 to 159.